Compare · NVO vs ZLAB
NVO vs ZLAB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zai Lab Limited (ZLAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZLAB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $218.21B, about 99.0x ZLAB ($2.20B).
- Over the past year, NVO is down 29.2% and ZLAB is down 43.7% - NVO leads by 14.5 points.
- ZLAB has been more active in the news (16 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 11 for ZLAB).
- Company
- Novo Nordisk A/S
- Zai Lab Limited
- Price
- $48.85-0.86%
- $19.33-1.48%
- Market cap
- $218.21B
- $2.20B
- 1M return
- +11.11%
- +9.46%
- 1Y return
- -29.15%
- -43.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 5
- 16
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Zai Lab Limited
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; Schrödinger, Inc.; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ZLAB
- Director Gaynor Richard bought $33,071 worth of American Depositary Shares (1,736 units at $19.05), increasing direct ownership by 2% to 80,737 units (SEC Form 4)
- Chairperson & CEO Du Ying converted options into 29,048 units of American Depositary Shares and covered exercise/tax liability with 11,431 units of American Depositary Shares, increasing direct ownership by 1% to 1,221,401 units (SEC Form 4)
- Chairperson & CEO Du Ying sold $130,220 worth of American Depositary Shares (7,026 units at $18.53) and converted options into 17,970 units of American Depositary Shares, increasing direct ownership by 0.92% to 1,203,784 units (SEC Form 4)
- Chief Legal Officer Edmondson Frazor Titus Iii converted options into 14,600 units of American Depositary Shares and sold $71,642 worth of American Depositary Shares (4,103 units at $17.46), increasing direct ownership by 53% to 30,346 units (SEC Form 4)
- Chairperson & CEO Du Ying converted options into 58,800 units of American Depositary Shares and sold $428,545 worth of American Depositary Shares (24,543 units at $17.46), increasing direct ownership by 3% to 1,192,840 units (SEC Form 4)
- Chief Financial Officer Chen Yajing converted options into 6,250 units of American Depositary Shares and sold $39,532 worth of American Depositary Shares (2,264 units at $17.46), increasing direct ownership by 13% to 35,691 units (SEC Form 4)
- Director Lis William sold $127,354 worth of American Depositary Shares (7,040 units at $18.09) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 50,437 units (SEC Form 4)
- Director Wirth Peter was granted 22,371 units of American Depositary Shares, increasing direct ownership by 6% to 416,121 units (SEC Form 4)
- Director Diekman John D was granted 22,371 units of American Depositary Shares, increasing direct ownership by 22% to 122,140 units (SEC Form 4)
- Director Morrison Scott W was granted 22,371 units of American Depositary Shares, increasing direct ownership by 65% to 56,904 units (SEC Form 4)